BACKGROUND: Although induction of activator protein-1 (AP-1) transcription factor activity has been observed in cardiac hypertrophy, a direct role for AP-1 in myocardial growth and gene expression remains obscure. METHODS AND RESULTS: Hypertrophy was induced in cultured neonatal rat cardiomyocytes with phenylephrine or overexpression of a constitutively active MAP3K, MKK6. In both treatment groups, induction of the pathological gene profile was observed, ie, expression of beta-myosin heavy chain (betaMHC), atrial/brain natriuretic peptides (ANP/BNP), and skeletal alpha-actin (sACT) was increased, whereas expression for alpha-myosin heavy chain (alphaMHC) and the sarcoplasmic reticulum Ca2+-ATPase (SERCA) genes was repressed. The role of AP-1 in the hypertrophic phenotype was evaluated with the use of an adenoviral construct expressing a dominant negative mutant of the c-Fos proto-oncogene (AdAFos). Although AFos did not change the myocyte growth response, it abrogated the gene profile to both agonists, including the upregulation of both alphaMHC and SERCA expression. CONCLUSIONS: Although c-Fos/AP-1 is necessary for induction of the pathological/fetal gene program, it does not appear to be critical for cardiomyocyte hypertrophy.
BACKGROUND: Although induction of activator protein-1 (AP-1) transcription factor activity has been observed in cardiac hypertrophy, a direct role for AP-1 in myocardial growth and gene expression remains obscure. METHODS AND RESULTS:Hypertrophy was induced in cultured neonatal rat cardiomyocytes with phenylephrine or overexpression of a constitutively active MAP3K, MKK6. In both treatment groups, induction of the pathological gene profile was observed, ie, expression of beta-myosin heavy chain (betaMHC), atrial/brain natriuretic peptides (ANP/BNP), and skeletal alpha-actin (sACT) was increased, whereas expression for alpha-myosin heavy chain (alphaMHC) and the sarcoplasmic reticulum Ca2+-ATPase (SERCA) genes was repressed. The role of AP-1 in the hypertrophic phenotype was evaluated with the use of an adenoviral construct expressing a dominant negative mutant of the c-Fos proto-oncogene (AdAFos). Although AFos did not change the myocyte growth response, it abrogated the gene profile to both agonists, including the upregulation of both alphaMHC and SERCA expression. CONCLUSIONS: Although c-Fos/AP-1 is necessary for induction of the pathological/fetal gene program, it does not appear to be critical for cardiomyocyte hypertrophy.
Authors: Susanne U Trost; Darrell D Belke; Wolfgang F Bluhm; Markus Meyer; Eric Swanson; Wolfgang H Dillmann Journal: Diabetes Date: 2002-04 Impact factor: 9.461
Authors: K Kinugawa; K Yonekura; R C Ribeiro; Y Eto; T Aoyagi; J D Baxter; S A Camacho; M R Bristow; C S Long; P C Simpson Journal: Circ Res Date: 2001-09-28 Impact factor: 17.367
Authors: Tetsuo Minamino; Toshiaki Yujiri; Naohiro Terada; George E Taffet; Lloyd H Michael; Gary L Johnson; Michael D Schneider Journal: Proc Natl Acad Sci U S A Date: 2002-03-12 Impact factor: 11.205
Authors: Stefan Frantz; Daniela Fraccarollo; Helga Wagner; Thomas M Behr; Philip Jung; Christiane E Angermann; Georg Ertl; Johann Bauersachs Journal: Cardiovasc Res Date: 2003-03 Impact factor: 10.787
Authors: Mark Y Jeong; John S Walker; R Dale Brown; Russell L Moore; Charles S Vinson; Wilson S Colucci; Carlin S Long Journal: Am J Physiol Heart Circ Physiol Date: 2010-04-02 Impact factor: 4.733
Authors: R Dale Brown; S Kelly Ambler; Min Li; Timothy M Sullivan; Lauren N Henry; Joseph T Crossno; Carlin S Long; Timothy P Garrington; Kurt R Stenmark Journal: Am J Physiol Heart Circ Physiol Date: 2012-11-02 Impact factor: 4.733
Authors: H Kiriazis; K Wang; Q Xu; X-M Gao; Z Ming; Y Su; X-L Moore; G Lambert; M E Gibbs; A M Dart; X-J Du Journal: Br J Pharmacol Date: 2008-01-14 Impact factor: 8.739